s
s
s
Antibodies for bioanalysis and drug monitoring of brentuximab vedotin and biosimilars
Develop highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for the antibody drug conjugate (ADC) brentuximab vedotin (Adcetris) using our range of ready-made antibodies.
Table 1. Antibodies Specific to Brentuximab Vedotin.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Brentuximab vedotin Inhibitory Type 1 |
HCA349 |
AbD39649 |
Fab-FH1 |
1.3 |
PK bridging ELISA |
|
HCA350 |
AbD39650ia |
Human IgG1 |
6 |
ADA control |
||
HCA351 |
AbD39655ia |
Human IgG1 |
0.7 |
PK bridging ELISA ADA control |
||
HCA352 |
AbD39659ia |
Human IgG1 |
1.4 |
ADA control |
* Affinity measured in the monovalent Fab format.
1 Monovalent Fab antibody with (F) DYKDDDDK-, and (H) His-6-tags.
Type 1 anti-brentuximab vedotin antibodies inhibit the binding of brentuximab vedotin to its target, human CD30. They recognize the brentuximab antibody alone, and when it is conjugated to the toxin, monomethyl auristatin E (MMAE). They are ideal for development of a PK bridging ELISA to measure free drug. Three clones are available in fully human IgG1 format for use as a surrogate positive control or reference standard in an ADA assay.
Fig. 1. Brentuximab vedotin PK bridging ELISA using antibodies HCA349 and HCA351.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 2. Brentuximab vedotin ADA bridging ELISA using antibody HCA350, HCA351, or HCA352.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.